NCT05597241View on ClinicalTrials.gov

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

October 15, 2022

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions

Major Depressive Disorder

Interventions

DRUG

apimostinel

N-methyl-D-aspartate (NMDA) receptor modulator

DRUG

Placebo

Placebo

Trial Locations (1)

72758

Woodland Research Northwest, Rogers

All Listed Sponsors

lead

Syndeio Biosciences, Inc

INDUSTRY